Ten reasons to choose dabigatran in everyday clinical practice Review article
Article Sidebar
Published:
Sep 30, 2014
Keywords:
atrial fibrillation, stroke prevention, dabigatran
Main Article Content
Abstract
Atrial fibrillation is a disease with very negative impact on not only the health status of the population, but also carrying a large socio-economic stigma. Not only because of the high incidence of patients, but also the enormous health effects associated with the consequences of its complications such as stroke. Effective anticoagulation with well-studied, modern drugs such as dabigatran is crucial for improving the prognosis of patients with atrial fibrillation.
Article Details
How to Cite
Szymański , F. M. (2014). Ten reasons to choose dabigatran in everyday clinical practice. Medycyna Faktow (J EBM), 7(3(24), 16-24. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2348
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm A.J., Kirchhof P., Lip G.Y. et al.: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 2010; 31: 2369-429.
2. Camm A.J., Lip G.Y., De Caterina R. et al.: ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 2012; 33: 2719-47.
3. Watson T., Shantsila E., Lip G.Y.: Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373: 155-66.
4. Wolf P.A., Abbott R.D., Kannel W.B.: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.
5. Goldstein L.B., Bushnell C.D., Adams R.J. et al.: American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, Council for High Blood Pressure Research, Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 517-84.
6. Jauch E.C., Saver J.L., Adams H.P. Jr et al.: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870-947.
7. Stewart S., Hart C.L., Hole D.J., McMurray J.J.: Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-21.
8. Go A.S., Hylek E.M., Phillips K.A. et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.
9. Krijthe B.P., Kunst A., Benjamin E.J. et al.: Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur. Heart J. 2013; 34: 2746-51.
10. Sanna T., Diener H.C., Passman R.S. et al.; CRYSTAL AF Investigators: Cryptogenic Stroke and Underlying Atrial Fibrillation. N. Engl. J. Med. 2014; 370: 2478-86.
11. Gladstone D.J., Spring M., Dorian P., Panzov V. et al.: Atrial Fibrillation in Patients with Cryptogenic Stroke. N. Engl. J. Med. 2014; 370: 2467-77.
12. Friberg L., Hammar N., Rosenqvist M.: Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur. Heart J. 2010; 31: 967-75.
13. Hart R.G., Pearce L.A., Aguilar M.I.: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 2007; 146: 857-67.
14. Husted S., de Caterina R., Andreotti F. et al.; ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease: Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb. Haemost. 2014; 111: 781-2.
15. Connolly S.J., Ezekowitz M.D., Yusuf S.L; RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139-51.
16. Patel M.R., Mahaffey K.W., Garg J. et al.; ROCKET AF Investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011; 365: 883-91.
17. Granger C.B., Alexander J.H., McMurray J.J. et al.; ARISTOTLE Committees and Investigators: Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011; 365: 981-92.
18. Majeed A., Hwang H.G., Connolly S.J. et al.: Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-32.
19. Bohm M.: Favorable effects of dabigatran versus warfarin on renal function change over time in patients with atrial fibrillation: results from the RE-LY Trial. ESC Congress 2014. Barcelona, Spain.
20. Kernan W.N., Ovbiagele B., Black H.R. et al.; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease: Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160-236.
21. Schulman S., Shortt B., Robinson M., Eikelboom J.W.: Adherence to anticoagulant treatment with dabigatran in a real-world setting. J. Thromb. Haemost. 2013; 11: 1295-9.
22. Desai N.R., Krumme A.A., Schneeweiss S. et al.: Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation – Quality and Cost Implications. Am. J. Med. 2014 May 20. pii: S0002-9343(14)00399-4. doi: 10.1016/j.amjmed.2014.05.013 [Epub ahead of print].
2. Camm A.J., Lip G.Y., De Caterina R. et al.: ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 2012; 33: 2719-47.
3. Watson T., Shantsila E., Lip G.Y.: Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373: 155-66.
4. Wolf P.A., Abbott R.D., Kannel W.B.: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.
5. Goldstein L.B., Bushnell C.D., Adams R.J. et al.: American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, Council for High Blood Pressure Research, Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 517-84.
6. Jauch E.C., Saver J.L., Adams H.P. Jr et al.: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870-947.
7. Stewart S., Hart C.L., Hole D.J., McMurray J.J.: Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-21.
8. Go A.S., Hylek E.M., Phillips K.A. et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.
9. Krijthe B.P., Kunst A., Benjamin E.J. et al.: Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur. Heart J. 2013; 34: 2746-51.
10. Sanna T., Diener H.C., Passman R.S. et al.; CRYSTAL AF Investigators: Cryptogenic Stroke and Underlying Atrial Fibrillation. N. Engl. J. Med. 2014; 370: 2478-86.
11. Gladstone D.J., Spring M., Dorian P., Panzov V. et al.: Atrial Fibrillation in Patients with Cryptogenic Stroke. N. Engl. J. Med. 2014; 370: 2467-77.
12. Friberg L., Hammar N., Rosenqvist M.: Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur. Heart J. 2010; 31: 967-75.
13. Hart R.G., Pearce L.A., Aguilar M.I.: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 2007; 146: 857-67.
14. Husted S., de Caterina R., Andreotti F. et al.; ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease: Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb. Haemost. 2014; 111: 781-2.
15. Connolly S.J., Ezekowitz M.D., Yusuf S.L; RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139-51.
16. Patel M.R., Mahaffey K.W., Garg J. et al.; ROCKET AF Investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011; 365: 883-91.
17. Granger C.B., Alexander J.H., McMurray J.J. et al.; ARISTOTLE Committees and Investigators: Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011; 365: 981-92.
18. Majeed A., Hwang H.G., Connolly S.J. et al.: Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-32.
19. Bohm M.: Favorable effects of dabigatran versus warfarin on renal function change over time in patients with atrial fibrillation: results from the RE-LY Trial. ESC Congress 2014. Barcelona, Spain.
20. Kernan W.N., Ovbiagele B., Black H.R. et al.; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease: Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160-236.
21. Schulman S., Shortt B., Robinson M., Eikelboom J.W.: Adherence to anticoagulant treatment with dabigatran in a real-world setting. J. Thromb. Haemost. 2013; 11: 1295-9.
22. Desai N.R., Krumme A.A., Schneeweiss S. et al.: Patterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation – Quality and Cost Implications. Am. J. Med. 2014 May 20. pii: S0002-9343(14)00399-4. doi: 10.1016/j.amjmed.2014.05.013 [Epub ahead of print].